araag2/HINT huggingface dataset:
Clinical trial NCT02737709 (phase 2, status: terminated)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: paclitaxel and carboplatin regimen
SMILES: [H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C
Reason stopped: 
    the study have difficulty in recruiting subjectes
  
Eligibility criteria:

        Inclusion Criteria:

          -  Age: 18 ~75 years

          -  Pathology: Confirmed by pathology (histology or cytology) for advanced non-small cell
             lung cancer

          -  Have indications of paclitaxel/carboplatin chemotherapy, suitable for paclitaxel
             chemotherapy (independent of clinical tumor stage or chemotherapy type or palliative
             chemotherapy lines)

          -  At least one measurable tumor lesions (according to RECIST 1.1 criteria)

          -  ECOG PS score: 0 to 2 points

          -  Life expectancy: more than 3 months

          -  Bone marrow reserve function is good, the function of organs (liver and kidney) is
             good, can satisfy the conditions of implementation chemotherapy. neutrophil count
             ≥1.5×109/l, platelet ≥75×109/l, hemoglobin >9g/dl, Total Bilirubin ≤1.5×ULN*,
             transaminase <2.5×ULN*, creatinine ≤1.5×ULN*,or creatinine clearance rate ≥45ml/min.
             ULR: Upper Limit Of Normal.

          -  Sign the informed consent form; Compliance is good, can be followed up, willing to
             comply with the requirements of the study

        Exclusion Criteria:

          -  ECOG Performance Scores > 2 points

          -  Organic disease (heart, liver, kidney disease etc), Active infection Organ
             transplantation immunosuppressive therapy, not capable to complete 4 - 6 cycles of
             paclitaxel / carboplatin chemotherapy.

          -  Any other tumor history not cured in 3 years before this trial.

          -  Bone marrow function or organs function not eligible for chemotherapy.

          -  Diabetic patients currently receiving the standard anti- diabetes treatment.
Clinical trial NCT02737891 (phase 2, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: tesofensine/metoprolol, placebo
SMILES: COCCC1=CC=C(OCC(O)CNC(C)C)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Males and females

          2. Confirmed diagnosis of T2DM

          3. 18-70 years of age

          4. HbA1c ≥7.0%

        Exclusion Criteria:

          1. Hypersensitivity to tesofensine/metoprolol

          2. Heart failure class II or greater according to the New York Heart Association (NYHA)
             or decompensated heart failure

          3. History of myocardial infarction or stroke within 12 months prior to enrolment

          4. History of coronary revascularisation or angioplasty in the last 12 months prior to
             enrolment

          5. Patients reporting angina in the last 6 months prior to enrolment

          6. Treatment with insulin and/or other injectable anti-diabetic medications, or TZDs

          7. Any clinically significant cardiac arrhythmia
Clinical trial NCT02738775 (phase 2, status: completed)
Conditions: multiple sclerosis
ICD codes: G35, C81.18
Drugs: placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of relapsed multiple sclerosis

          -  Active disease

          -  Greater than 1 relapse in prior 2 years

        Exclusion Criteria:

          -  Treatment with anti-CD20 monoclonal antibody within the last 12 months

          -  Treatment with alemtuzumab within the last 12 months

          -  Pregnant or nursing mothers
Clinical trial NCT02738801 (phase 2, status: completed)
Conditions: idiopathic pulmonary fibrosis
ICD codes: J84.112
Drugs: glpg1690 600 mg qd, placebo qd
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Subjects able and willing to sign the Institutional Review Board (IRB)/Independent
             Ethics Committee (IEC) approved Informed Consent Form (ICF)

          2. Male or female subjects of non-child-bearing potential aged ≥ 40 years

          3. Subjects with a chest HRCT performed within 12 months prior to screening

          4. Subjects with IPF diagnosed by a multidisciplinary team

          5. Subjects with: a. forced vital capacity (FVC) ≥50% predicted of normal AND b.
             Diffusing capacity for the lungs for carbon monoxide (DLCO) ≥ 30% predicted of normal
             corrected for hemoglobin

          6. Subjects with a forced expiratory volume in 1 second (FEV1)/FVC (Tiffeneau-Pinelli
             index) ratio ≥ 0.70 (based on pre-bronchodilator spirometry

          7. Subjects on stable supportive care

          8. Subjects in stable condition

        Exclusion Criteria:

          1. Subjects with know hypersensitivity to any of the study drug ingredients

          2. Subjects with a history of or current immunosuppressive condition

          3. Subjects with a history of malignancy within the past 5 years

          4. Subjects with clinically significant abnormalities on ECG

          5. Subjects with acute IPF exacerbation within 6 weeks prior to screening

          6. Subjects with a lower respiratory tract infection requiring antibiotics with 4 weeks
             prior to screening

          7. Smoking within 3 months pre-screening

          8. Interstitial lung disease

          9. History of lung volume reduction surgery or lung transplant

         10. Unstable cardiac or pulmonary disease other than IPF within 6 months prior to
             screening

         11. Subjects with abnormal liver function

         12. Subjects with abnormal renal function
Clinical trial NCT02740972 (phase 2, status: completed)
Conditions: duchenne muscular dystrophy
ICD codes: G71.01
Drugs: ns-065/ncnp-01, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male ≥ 4 years and <10 years of age

          -  Confirmed DMD mutation(s) in the dystrophin gene that is amenable to skipping of exon
             53 to restore the dystrophin mRNA reading frame;

          -  Able to walk independently without assistive devices;

          -  Ability to complete the time to stand, time to run/walk and time to climb assessments;

          -  Stable dose of glucocorticoid for at least 3 months

        Exclusion Criteria:

          -  Acute illness within 4 weeks prior to the first dose of study medication;

          -  Evidence of symptomatic cardiomyopathy. [Note: Asymptomatic cardiac abnormality on
             investigation would not be exclusionary];

          -  Severe allergy or hypersensitivity to medications;

          -  Severe behavioral or cognitive problems that preclude participation in the study, in
             the opinion of the Investigator;

          -  Previous or ongoing medical condition, medical history, physical findings or
             laboratory abnormalities that could affect safety, make it unlikely that treatment and
             follow-up will be correctly completed or impair the assessment of study results, in
             the opinion of the Investigator;

          -  Patient is taking any other investigational drug currently or within 3 months prior to
             the start of study treatment; or

          -  Patient has had surgery within the 3 months prior to the first anticipated
             administration of study medication or surgery is planned for anytime during the
             duration of the study;

          -  Patient has previously participated in this study or any other study during which
             NS-065/NCNP-01 was administered.
Clinical trial NCT02743221 (phase 2, status: completed)
Conditions: metastatic colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: trifluridine/tipiracil + bevacizumab, capecitabine + bevacizumab
SMILES: ClC1=C(CN2CCCC2=N)NC(=O)NC1=O, CCCCCOC(=O)NC1=NC(=O)N(C=C1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Written informed consent obtained.

          -  Has ECOG (Eastern Cooperative Oncology Group) performance status of 0, 1 or 2 at the
             time of the randomisation.

          -  Has definitive histologically or cytologically confirmed adenocarcinoma of the colon
             or rectum.

          -  RAS status must have been determined (mutant or wild).

          -  Has at least one measurable metastatic lesion.

          -  No previous systemic anticancer therapy for unresectable metastatic colorectal cancer.

          -  Previous adjuvant (or neoadjuvant for patients with rectal cancer) chemotherapy is
             allowed only if if it has been completed more than 6 months before start of study
             treatment.

          -  Patient is not a candidate for combination chemotherapy with irinotecan or
             oxaliplatin, or for curative resection of metastatic lesions.

          -  Is able to take medication orally (i.e., no feeding tube).

          -  Has adequate organ function.

          -  Coagulation parameters in normal limit (or in therapeutic limit for patients treated
             with anticoagulant drugs).

          -  Women of childbearing potential must have been tested negative in a serum pregnancy
             test. Female participants of childbearing potential and male participants with
             partners of childbearing potential must agree to use a highly effective method of
             birth control. Women and female partners using hormonal contraceptive must also use a
             barrier method.

        Exclusion Criteria:

          -  Is a pregnant or lactating female.

          -  Has certain serious illness or serious medical condition(s) as described in the
             protocol.

          -  Has had certain other recent treatment e.g. major surgery, field radiation, received
             investigational agent, within the specified time frames prior to randomisation.

          -  Has previously received Trifluridine/tipiracil or history of allergic reactions
             attributed to compounds of similar composition to Trifluridine/tipiracil or any of its
             excipients.

          -  Has rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or
             glucose-galactose malabsorption.

          -  Has contra-indication to bevacizumab or capecitabine.
Clinical trial NCT02745353 (phase 2, status: terminated)
Conditions: constipation
ICD codes: K59.00, K59.09, K59.01, K59.02, K59.03, K59.04, K58.1
Drugs: naloxegol
SMILES: COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3CC4=CC=C(O)C5=C4[C@@]2(CCN3CC=C)[C@H]1O5
Reason stopped: 
    couldn't enough accrue patients
  
Eligibility criteria:

        Inclusion Criteria:

          -  Adults greater than or equal to 18 years old.

          -  Eastern Cooperative Oncology Group (ECOG) less than or equal to 3.

          -  Glomerular filtration rate (GFR) greater than or equal to 30 ml/min/1.73m2 by
             Modification of Diet in Renal Disease (MDRD).

          -  Corrected serum calcium level less than or equal to 10.5 mg/dL.

          -  Estimated life expectancy greater than or equal to 6 months.

          -  Negative pregnancy test prior to initiating study treatment for females of
             childbearing potential.

        Exclusion Criteria:

          -  Patients receiving the following medications within 3 days of Study Day 1 and/or are
             planned to receive throughout the duration of the study period: opioid antagonist,
             mixed antagonist, a strong CYP3A4 and/or P-glycoprotein (P-gp) inhibitor, a moderate
             CYP3A4 and/or P-gp inhibitor, and/or a strong CYP3A4 inducer.

          -  Concurrent total parenteral nutrition and/or use of metoclopramide.

          -  Patients at high risk for bowel perforation.

          -  Constipation that was not primarily caused by opioids in the investigator's medical
             opinion.

          -  A condition that may have affected the permeability of the blood-brain barrier (e.g.,
             known brain metastases, meningeal metastases, brain injury, multiple sclerosis, recent
             brain injury, uncontrolled epilepsy)

          -  Patient has clinically active diverticular disease.

          -  Past medical history of irritable bowel syndrome, signs of active gastrointestinal
             (GI) bleeding, acute surgical abdomen, bowel stents, indwelling peritoneal catheter,
             mechanical GI obstruction, fecal impaction, or fecal ostomy.

          -  Patient has motility/neurologic disorders including autonomic failure (spinal cord
             lesions, tumor invasion of nerves) and/or poorly controlled endocrine/metabolic
             disorders (hypercalcemia, hypokalemia, diabetes, hypothyroidism), as determined by the
             investigator.

          -  Uncontrolled cancer pain despite analgesic therapy
Clinical trial NCT02745561 (phase 2, status: unknown status)
Conditions: esophageal cancer, endostatin
ICD codes: K22.2, K22.81, Q39.4, P78.83, I85.00, I85.01, I85.10
Drugs: endostatins, oxaliplatin
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          1. Cytologically or histologically confirmed esophageal carcinoma

          2. Age of 18 -80

          3. ECOG performance status: 0-1;

          4. No treatments prior to enrollment;

          5. At least one measurable lesion on CT, MRI or esophageal barium exam;

          6. Normal functions of heart, lung, liver, kidney and bone marrow Blood exams qualified
             for chemotherapy, which included hemoglobulin ≥9 g/dl, neutrophil ≥1.5×109/L and
             platelet (PLT) ≥100×109/L, creatinine ≤1.5 UNL

          7. Informed consent signed

        Exclusion Criteria:

          1. Prior treatments of chemotherapy or irradiation;

          2. Poor bone marrow, liver and kidney functions, which would make chemotherapy
             intolerable;

          3. Contraindication for irradiation: complete obstruction of esophagus, deep esophageal
             ulcer, fistula to mediastinum, or haematemesis;

          4. Participating in other clinical trials;

          5. Pregnancy, breast feeding, or not adopting birth control;

          6. Clinically significant and uncontrolled major medical conditions including but not
             limited to: active uncontrolled infection, symptomatic congestive heart failure,
             Unstable angina pectoris or cardiac arrhythmia, psychiatric illness/ social situation
             that would limit compliance with study requirements; any medical condition, which in
             the opinion of the study investigator places the subject at an unacceptably high risk
             for toxicities

          7. The subject has had another active malignancy within the past five years except for
             cervical cancer in site, in situ carcinoma of the bladder or non-melanoma carcinoma of
             the skin;
Clinical trial NCT02747004 (phase 2, status: active, not recruiting)
Conditions: metastatic breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: abemaciclib, tamoxifen, prophylactic loperamide
SMILES: CCN1CCN(CC2=CC=C(NC3=NC=C(F)C(=N3)C3=CC(F)=C4N=C(C)N(C(C)C)C4=C3)N=C2)CC1, OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2, O[Bi]1OC(=O)C2=CC=CC=C2O1
Eligibility criteria:

        Inclusion Criteria:

          -  Have a diagnosis of HR+, HER2- breast cancer.

          -  Relapsed or progressed following endocrine therapy.

          -  Have received prior treatment with at least 2 chemotherapy regimens, of which at least
             1 but no more than 2 have been administered in the metastatic setting.

          -  Have the presence of measureable disease as defined by the Response Evaluation
             Criteria in Solid Tumors (RECIST 1.1).

          -  Have a performance status ≤1 on the Eastern Cooperative Oncology Group (ECOG) scale.

          -  Have discontinued previous therapies for cancer (including specifically, aromatase
             inhibitors, anti-estrogens, chemotherapy, radiotherapy, and immunotherapy) for at
             least 21 days for myelosuppressive agents or 14 days for nonmyelosuppressive agents
             prior to receiving study drug, and recovered from the acute effects of therapy (until
             the toxicity resolves to either baseline or at least Grade 1) except for residual
             alopecia or peripheral neuropathy.

          -  Have adequate organ function.

          -  Have negative serum pregnancy test within 7 days prior to the first dose of study
             treatment and agree to use highly effective precautions to prevent pregnancy during
             the study and for 3 weeks following last dose of study treatment.

          -  Are able to swallow oral medication.

        Exclusion Criteria:

          -  Have clinical evidence or history of central nervous system metastasis.

          -  Have a personal history of any of the following conditions: syncope of either
             unexplained or cardiovascular etiology, ventricular tachycardia, ventricular
             fibrillation, or sudden cardiac arrest.

          -  Have active bacterial or fungal infection (that is, requiring intravenous antibiotics
             at the time of initiating study treatment) and/or detectable viral infection.

          -  Have received treatment with a prior cyclin-dependent kinase (CDK4) and CDK 6
             inhibitor.

          -  Have a preexisting chronic condition resulting in persistent diarrhea.

          -  Have a history of any other cancer (except nonmelanoma skin cancer or carcinoma
             in-situ of the cervix or breast), unless in complete remission with no therapy for a
             minimum of 3 years.
Clinical trial NCT02749136 (phase 2, status: completed)
Conditions: pancreatic adenocarcinoma
ICD codes: C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31
Drugs: preoperative modified folfirinox and postoperative gemcitabine
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients aged 19 years and older

          -  Cytologically or histologically confirmed adenocarcinoma of the pancreas

          -  Met the NCCN criteria for borderline resectable disease (assessed at Aug 23rd, 2015)

          -  No previous chemotherapy or radiotherapy

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 ~ 1

          -  Adequate bone marrow function as defined by platelets ≥ 100 x 109/L and neutrophils ≥
             1.5 x 109/L

          -  Adequate renal function, with serum creatinine < 1.5 x upper limit of normal (ULN)

          -  Adequate hepatic function with serum total bilirubin < 2 mg/dL, alanine
             aminotransferase (ALT) or aspartate aminotransferase (AST) < 2.5 x ULN

          -  No other malignant disease apart from non-melanotic skin cancer or carcinoma in situ
             of the uterine cervix or any other non life-threatening cancer (i.e., prostate or
             thyroid cancer) except where treated with curative intent > 5 years previously without
             evidence of relapse

          -  Written informed consent to the study

        Exclusion Criteria:

          -  No potentially resectable disease or no metastatic disease

          -  Locally advanced unresectable disease according to the NCCN criteria

          -  Histologically confirmed adenosquamous carcinoma

          -  Medical or psychiatric conditions that compromise the patient's ability to give
             informed consent or to complete the protocol or a history of non-compliance

          -  Last dose of radiotherapy received within 4 weeks before the start of study treatment,
             excluding palliative radiotherapy

          -  Obstruction of gastrointestinal tract

          -  Active gastrointestinal bleeding

          -  Myocardial infarction within 6 months prior to the study medication, and other
             clinically significant heart disease (e.g., unstable angina, congestive heart failure
             or uncontrolled hypertension)

          -  Evidence of severe or uncontrolled systemic disease or any concurrent condition which
             in the investigator's opinion makes it undesirable for the patient to participate in
             the study or which would jeopardise compliance with the protocol

          -  Female subjects who are pregnant or lactating, or males and females of reproductive
             potential not willing or not able to employ a highly effective method of birth
             control/contraception to prevent pregnancy from 2 weeks before receiving study drug
             until 3 months after receiving the last dose of study drug. A highly effective method
             of contraception is defined as having a low failure rate (< 1% per year) when used
             consistently and correctly.
Clinical trial NCT02752880 (phase 2/phase 3, status: completed)
Conditions: type 2 diabetes
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: yh1 group, placebo group
SMILES: [Na+].[Cl-]
Eligibility criteria:

        Inclusion Criteria:

          1. 20-75 years of age;

          2. Diagnosed as type 2 diabetics based on World Health Organization criteria [1];

          3. Body mass index (BMI) ≥ 23 kg/m2;

          4. Have been treated with ≥ 3 kinds of oral hypoglycemic agents (OHAs) with persistent (>
             6 months) high HbA1c (≥ 7.0 %).

        Exclusion Criteria:

          1. Type 1 diabetes, gestational diabetes, or other specific types of diabetes;

          2. Have received insulin therapy in the past three months;

          3. Have serious gastrointestinal (GI) tract diseases, such as peptic ulcers or GI tract
             bleeding;

          4. Experience stressful situations, including diabetic ketoacidosis, nonketotic
             hyperosmolar diabetic coma, severe infection, or surgery in the previous one month;

          5. Suffer from hepatic insufficiency with alanine aminotransferase (ALT) 2 times the
             upper limit of normal or renal insufficiency with estimated glomerular filtration rate
             (eGFR) < 60;

          6. Uncontrolled hypertension (blood pressure ≥ 160/100 mmHg);

          7. Mental illness, abused or addicted to alcohol, psychoactive substances or other drugs;

          8. Pregnant, lactating, or plan to become pregnant;

          9. Hemoglobin disease or chronic anemia;

         10. Have underlying conditions that could lead to poor compliance;

         11. History of cerebrovascular disease or myocardial infarction;

         12. Have undergone Chinese medicine treatment in the past two weeks.